GlassScriptPhysician profile
Melissa M Veil
NPI 1225426943
$2,193.38
in general payments reported to CMS, 2019-2025
19 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.31 · 2023: $48.63 · 2024: $463 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.07 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.95 | 2024-2025 | |
| Madrigal Pharmaceuticals | $226.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $187.31 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $184.26 | 2024-2025 | Tremfya |
| Gilead Sciences, INC. | $108.64 | 2024 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $107.80 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $103.51 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $78.63 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $65.79 | 2025 | Iqirvo |
| Genzyme Corporation | $58.47 | 2024 | |
| Intercept Pharmaceuticals, INC. | $56.69 | 2025 | |
| Lilly USA, LLC | $50.99 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.64 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $41.63 | 2025 | Voquezna |
| Aurinia Pharma U.S., INC. | $28.39 | 2023 | Lupkynis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22.92 | 2024 | Dupixent |
| Braintree Laboratories, INC. | $21.03 | 2025 | Suflave, Sutab |
| Tactile Systems Technology INC | $20.24 | 2023 | Entre Plus, Flexitouch Plus |
| Biocon Biologics INC | $16.69 | 2025 | Yesintek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Veil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.